Ruella M, Kalos M. Adoptive immunotherapy for cancer. Immunol Rev. 2014;257:14–38.
Tao R, Han X, Bai X, Yu J, Ma Y, Chen W, Zhang D, Li Z. Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR/Cas9 gene editing technology. Front Immunol. 2024;15:1354825.
Article CAS PubMed PubMed Central Google Scholar
Yang M, Chen L, Wang J, Msigwa G, Osman AI, Fawzy S, Rooney DW, Yap P-S. Circular economy strategies for combating climate change and other environmental issues. Environ Chem Lett. 2023;21:55–80.
Porter DL, Hwang W-T, Frey NV, Lacey SF, Shaw PA, Loren AW, Bagg A, Marcucci KT, Shen A, Gonzalez V. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015;7:303139.
Bouchkouj N, Kasamon YL, de Claro RA, George B, Lin X, Lee S, Blumenthal GM, Bryan W, McKee AE, Pazdur R. FDA approval summary: axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma. Clin Cancer Res. 2019;25:1702–8.
Locke FL, Neelapu SS, Bartlett NL, Siddiqi T, Chavez JC, Hosing CM, Ghobadi A, Budde LE, Bot A, Rossi JM. Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol Ther. 2017;25:285–95.
Article CAS PubMed PubMed Central Google Scholar
Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531–44.
Article CAS PubMed PubMed Central Google Scholar
Gross G, Gorochov G, Waks T, Eshhar Z. Generation of effector T-cells expressing chimeric T-cell receptor with antibody type-specificity. Transpl Proc. 1989;21:127–30.
Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci. 1993;90:720–4.
Article CAS PubMed PubMed Central Google Scholar
Ruella M, Korell F, Porazzi P, Maus MV. Mechanisms of resistance to chimeric antigen receptor-T cells in haematological Malignancies. Nat Rev Drug Discovery. 2023;22:976–95.
Article CAS PubMed Google Scholar
Maalej KM, Merhi M, Inchakalody VP, Mestiri S, Alam M, Maccalli C, Cherif H, Uddin S, Steinhoff M, Marincola FM. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol Cancer. 2023;22:20.
Article CAS PubMed PubMed Central Google Scholar
Liu Q, Hu T, Li H, Shen Y, Wu D, Ye B. Prolonged haematologic toxicity in CAR-T-cell therapy: a review. J Cell Mol Med. 2023;27:3662–71.
Article CAS PubMed PubMed Central Google Scholar
Peters DT, Savoldo B, Grover NS. Building safety into CAR-T therapy. Hum Vaccin Immunother. 2023;19:2275457.
Article PubMed PubMed Central Google Scholar
Miao L, Zhang Z, Ren Z, Tang F, Li Y. Obstacles and coping strategies of CAR-T cell immunotherapy in solid tumors. Front Immunol. 2021;12: 687822.
Article CAS PubMed PubMed Central Google Scholar
Awasthi R, Maier HJ, Zhang J, Lim S. Kymriah®(tisagenlecleucel)–an overview of the clinical development journey of the first approved CAR-T therapy. Hum Vaccin Immunother. 2023;19:2210046.
Article PubMed PubMed Central Google Scholar
Hou B, Tang Y, Li W, Zeng Q, Chang D. Efficiency of CAR-T therapy for treatment of solid tumor in clinical trials: a meta-analysis. Dis Markers. 2019;2019:3425291.
Article PubMed PubMed Central Google Scholar
Maher J, Wilkie S, Davies DM, Arif S, Picco G, Julien S, Foster J, Burchell J, Taylor-Papadimitriou J. Targeting of tumor-associated glycoforms of MUC1 with CAR T cells. Immunity. 2016;45:945–6.
Article CAS PubMed Google Scholar
Liu Q, Yang J, Xing Y, Zhao Y, Liu Y. Development of delivery strategies for CRISPR-Cas9 genome editing. BMEMat. 2023;1: e12025.
Chmielewski M, Hombach AA, Abken H. Of CAR s and TRUCK s: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunol Rev. 2014;257:83–90.
Article CAS PubMed Google Scholar
Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, Kamble RT, Bollard CM, Gee AP, Mei Z. CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients. J Clin Investig. 2011;121:1822–6.
Article CAS PubMed PubMed Central Google Scholar
Enblad G, Karlsson H, Gammelgård G, Wenthe J, Lövgren T, Amini RM, Wikstrom KI, Essand M, Savoldo B, Hallböök H. A phase I/IIa trial using CD19-targeted third-generation CAR T cells for lymphoma and leukemia. Clin Cancer Res. 2018;24:6185–94.
Article CAS PubMed Google Scholar
Ramos CA, Rouce R, Robertson CS, Reyna A, Narala N, Vyas G, Mehta B, Zhang H, Dakhova O, Carrum G. In vivo fate and activity of second-versus third-generation CD19-specific CAR-T cells in B cell non-Hodgkin’s lymphomas. Mol Ther. 2018;26:2727–37.
Article CAS PubMed PubMed Central Google Scholar
Pegram H, Purdon T, Van Leeuwen D, Curran K, Giralt S, Barker J, Brentjens R. IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia. Leukemia. 2015;29:415–22.
Article CAS PubMed Google Scholar
Ren J, Liu X, Fang C, Jiang S, June CH, Zhao Y. Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin Cancer Res. 2017;23:2255–66.
Article CAS PubMed Google Scholar
Urbanska K, Lanitis E, Poussin M, Lynn RC, Gavin BP, Kelderman S, Yu J, Scholler N, Powell DJ Jr. A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor. Can Res. 2012;72:1844–52.
Cho JH, Collins JJ, Wong WW. Universal chimeric antigen receptors for multiplexed and logical control of T cell responses. Cell. 2018;173:1426-38.e1411.
Article CAS PubMed PubMed Central Google Scholar
Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Sem Radiat Oncol Sem Radiat Oncol. 2004;14:198–206.
Rofstad EK, Gaustad JV, Egeland TA, Mathiesen B, Galappathi K. Tumors exposed to acute cyclic hypoxic stress show enhanced angiogenesis, perfusion and metastatic dissemination. Int J Cancer. 2010;127:1535–46.
Article CAS PubMed Google Scholar
Matsuoka T, Yashiro M. Molecular insight into gastric cancer invasion—current status and future directions. Cancers. 2023;16:54.
Article PubMed PubMed Central Google Scholar
Tang E, Wang Y, Liu T, Yan B. Gastrin promotes angiogenesis by activating HIF-1α/β-catenin/VEGF signaling in gastric cancer. Gene. 2019;704:42–8.
Article CAS PubMed Google Scholar
Clambey ET, McNamee EN, Westrich JA, Glover LE, Campbell EL, Jedlicka P, De Zoeten EF, Cambier JC, Stenmark KR, Colgan SP. Hypoxia-inducible factor-1 alpha–dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa. Proc Natl Acad Sci. 2012;109:E2784–93.
Comments (0)